Disc Medicine announced initial results from the RESTORE-PV Phase 2 clinical trial of DISC-3405 in patients with polycythemia vera. The open-label study enrolled 40 participants, with efficacy data presented for Cohort A (n=13 completed 26 weeks). Treatment significantly reduced mean phlebotomy events from 4.0 to 0.6 per 26 weeks (p<0.0001), and 61.5% of patients remained entirely phlebotomy-free through week 26. DISC-3405 maintained hematocrit stably below 45% and was generally well-tolerated with mild injection site reactions. The company plans to provide updates on RESTORE-PV and a Phase 1b trial in sickle cell disease by the end of 2026, alongside FDA feedback for selcodebart in myelofibrosis. Disc Medicine is a clinical-stage biopharmaceutical company focused on discovering and developing novel treatments for serious hematologic diseases.

Disc Medicine reported second quarter 2026 financial results with a net loss of $59.5 million and R&D expenses of $46.9 million. The company ended the period with approximately $718 million in cash, providing operational runway into 2029. Clinically, Disc Medicine completed enrollment for the Phase 2 RESTORE-PV study of DISC-3405 in polycythemia vera and launched an Expanded Access Program for bitopertin in erythropoietic protoporphyria (EPP). The company aligned with the FDA that a successful Phase 3 APOLLO trial could support regulatory approval, with topline data expected in Q4 2026. Disc Medicine operates as a clinical-stage biopharmaceutical company focused on discovering and developing treatments for serious hematologic diseases.

Disc Medicine, Inc. entered into a First Amendment to its Loan and Security Agreement with Hercules Capital, Inc. to extend drawing periods for future Advances. The Company agreed to draw down $30,000,000 of the Tranche 1-B Advance, restructured the existing $50,000,000 Tranche 1-C Advance into two $25,000,000 portions, and extended the drawing periods for Tranche 2 and Tranche 3 Advances to December 15, 2027, and June 30, 2028, respectively. The amendment also modified minimum cash covenant testing to an initial date of July 1, 2028. Disc Medicine, Inc. is a biotechnology company focused on developing medical treatments for rare diseases.